Rigel Pharmaceuticals Inc. (New) (RIGL)
NASDAQ · Manufacturing · Pharmaceutical preparations
$48.18+$0.2900 (+0.61%) on the dayAs of the close; data may be delayed.
RIGL price, last 12 months
Key stats
- Previous close
- $47.89
- Open
- $48.23
- Day range
- $47.20 – $48.53
- 52-week range
- $24.95 – $52.24
- Volume
- 108.2K
- Avg volume (20 days)
- 233.4K
- Market cap
- $900.0M
Performance
1W+3.3%
1M+3.7%
3M+24.5%
6M+82.7%
YTD+12.5%
1Y+59.1%
vs S&P 500, 1Y+42.3 pts
Technicals and fundamentals
About Rigel Pharmaceuticals Inc. (New)
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $900.0M